Addex Therapeutics Ltd., a biopharmaceutical company operating within the health care sector, has recently disclosed its half-year financial results and corporate update for 2026. The company, which specializes in developing allosteric modulators for human health care, has made significant strides in advancing its research and development initiatives.
A key development for Addex Therapeutics is the successful completion of a market-based fundraising round. This capital infusion is earmarked to propel the company’s in-house GABAB chronic cough program forward. Additionally, the company has regained full rights to its GABAB positive-allosteric-modulator portfolio following a merger-related rationalization with Indivior. This strategic move is expected to bolster Addex’s position in the biotechnology industry.
In parallel, the spin-out entity Neurosterix is making progress with its Phase 1 study of an M4 PAM candidate aimed at treating schizophrenia. The study is anticipated to conclude in the final quarter of 2026, marking a significant milestone in the company’s pipeline.
From a financial perspective, Addex Therapeutics reported that its operating expenses have remained broadly stable. This stability is attributed to modest reductions in research and development costs, which have been partially offset by increased share losses from Neurosterix. Despite these efforts, the company’s cash balances have seen a decline compared to the previous year. This reduction is primarily due to ongoing operating activities and the sale of treasury shares.
In terms of market performance, Addex Therapeutics is listed on the SIX Swiss Exchange, with a market capitalization of 2,940,000 CHF. The company’s share price closed at 0.0246 CHF on September 24, 2026. Over the past year, the share price has fluctuated, reaching a 52-week high of 0.069 CHF on August 20, 2026, and a 52-week low of 0.022 CHF on September 15, 2026. The price-to-earnings ratio stands at -0.43, reflecting the company’s current financial standing.
Looking ahead, Addex Therapeutics remains committed to its strategic focus on developing novel small-molecule modulators for neurological disorders. The company has also announced upcoming conference call details for investors, providing an opportunity for stakeholders to gain further insights into its strategic direction and future prospects.
Overall, Addex Therapeutics Ltd. continues to navigate the complexities of the biotechnology sector with a clear focus on innovation and strategic growth, positioning itself as a key player in the development of therapeutic solutions for neurological conditions.
